Gail Folena-wasserman PhD

Dr. Gail Folena-Wasserman is the Head of Biopharmaceutical Development at MedImmune and has oversight of all analytical, process, formulation and drug product development including delivery and devices; and clinical manufacturing and quality control for clinical products. Dr. Folena-Wasserman is responsible for research support, early and late-stage development, clinical manufacturing phases I-III, technology transfer, and lifecycle management.

She joined MedImmune in 1991 as director, development, and was promoted to vice president, development, in October 1995. In 2010, she has appointed the head of vaccines and biologics development. Dr. Folena-Wasserman established the Biopharmaceutical Development (BPD) function and Clinical Manufacturing Capabilities (CMC) at MedImmune. Following the MedImmune acquisition by AstraZeneca, she led the transition from three development divisions (AZ biologics, Cambridge Antibody Technology, MedImmune) to the current biopharmaceutical development organization.

Prior to joining the company, Dr. Folena-Wasserman spent nine years in natural products isolation and biopharmaceutical process development at SmithKline Beecham Pharmaceuticals. She holds four patents. PharmaVOICE selected Dr. Folena-Wasserman as one of the 100 Most Inspiring People in 2011. Dr. Folena-Wasserman holds a bachelor’s degree in biology and chemistry from Montclair State University in New Jersey and received a master’s degree in biochemistry and a doctorate in chemistry from The Pennsylvania State University.